{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:18:31Z","timestamp":1760347111777,"version":"3.40.5"},"reference-count":11,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Phenprocoumon is a vitamin K antagonist that is widely prescribed in Europe\nand Latin America for the prophylaxis and treatment of thromboembolic events.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation:<\/jats:title>\n<jats:p>A 90-year-old female was admitted to our hospital with tonic-clonic seizures,\npossibly due to dementia syndrome.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Valproic acid (VPA) was prescribed for the treatment of seizures. VPA is an inhibitor of cytochrome\nP450 (CYP) 2C9 enzymes. A pharmacokinetic interaction with phenprocoumon occurred,\nwhich is a substrate for CYP2C9 enzymes. The interaction resulted in a strong INR increase and\nsubsequent clinically relevant bleeding in our patient.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Valproic acid is not specifically mentioned in the phenprocoumon drug label as a CYP2C9 inhibitor,\nand in the Dutch medication surveillance database, no medication alert is shown when prescribing\nthis combination, and no interaction with phenprocoumon has been reported so far.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>When prescribing this combination, the prescriber should be warned and advised to\nintensify INR monitoring if the combination is to be continued.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886318666230310104322","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T11:57:58Z","timestamp":1678449478000},"page":"142-144","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bleeding Complications in a Patient After the Unexpected Interaction\nbetween Valproic Acid and Phenprocoumon"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0413-5204","authenticated-orcid":true,"given":"Andr\u00e9","family":"Wieringa","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Isala Hospital, Zwolle, The Netherlands"},{"name":"Department of Clinical Pharmacology,\nIsala Hospital, Zwolle, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle-Brit","family":"Fiebrich","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology,\nIsala Hospital, Zwolle, The Netherlands"},{"name":"Department of Oncology, Isala Hospital, Zwolle, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fleur van","family":"Gelder","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Isala Hospital, Zwolle, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham J.","family":"Valkenburg","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology,\nIsala Hospital, Zwolle, The Netherlands"},{"name":"Department of Intensive Care, Isala Hospital, Zwolle, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan G.","family":"Maring","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Isala Hospital, Zwolle, The Netherlands"},{"name":"Department of Clinical Pharmacology,\nIsala Hospital, Zwolle, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise J.","family":"Smolders","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Isala Hospital, Zwolle, The Netherlands"},{"name":"Department of Clinical Pharmacology,\nIsala Hospital, Zwolle, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1160\/TH08-11-0730","volume":"102","author":"Palareti G.","year":"2009","unstructured":"Palareti G.; Cosmi B.; Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost 2009,102(2),268-278","journal-title":"Thromb Haemost"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/157015910792246254","volume":"8","author":"Johannessen S.I.","year":"2010","unstructured":"Johannessen S.I.; Landmark C.J.; Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol 2010,8(3),254-267","journal-title":"Curr Neuropharmacol"},{"author":"Sanofi-Aventis NBV","key":"ref=3","unstructured":"Sanofi-Aventis NBV;  Summary of product characteristics: Depakin 500 mg. Available from:  [Accessed on: April 13, 2022]."},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199504000-00010","author":"Flockhart D.A.","year":"2021","unstructured":"Flockhart D.A.; Thacker D.; McDonald C.; Desta Z.; The flockhart cytochrome P450 drug-drug interaction table. Division of Clinical Pharmacology, Indiana University School of Medicine. 2021"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40360-018-0251-0","volume":"19","author":"Zhou C.","year":"2018","unstructured":"Zhou C.; Sui Y.; Zhao W.; The critical interaction between valproate sodium and warfarin: Case report and review. BMC Pharmacol Toxicol 2018,19(1),60","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12028-011-9544-5","volume":"15","author":"Yoon H.W.","year":"2011","unstructured":"Yoon H.W.; Giraldo E.A.; Wijdicks E.F.M.; Valproic acid and warfarin: An underrecognized drug interaction. Neurocrit Care 2011,15(1),182-185","journal-title":"Neurocrit Care"},{"author":"Sandoz BV","key":"ref=7","unstructured":"Sandoz BV;  Summary of product characteristics: Phenprocoumon. Available from:  [Accessed on: April 13, 2022]."},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/clpt.1980.235","volume":"28","author":"Perucca E.","year":"1980","unstructured":"Perucca E.; Hebdige S.; Frigo G.M.; Gatti G.; Lecchini S.; Crema A.; Interaction between phenytoin and valproic acid: Plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980,28(6),779-789","journal-title":"Clin Pharmacol Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"Horn J.R.","year":"2007","unstructured":"Horn J.R.; Hansten P.D.; Chan L.N.; Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007,41(4),674-680","journal-title":"Ann Pharmacother"},{"key":"ref=10","unstructured":"Federation of Dutch Thrombosis Services. Available from:  [Accessed on: April 13, 2022]."},{"key":"ref=11","unstructured":"Drug Interactions Flockhart Table. Available from:  [Accessed on: April 13, 2022]."}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886318666230310104322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/214547\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886318666230310104322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T12:39:33Z","timestamp":1701693573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/214547\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886318666230310104322","relation":{},"ISSN":["1574-8863"],"issn-type":[{"type":"print","value":"1574-8863"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}